Drug maker Acambis said it had started a Phase II clinical trial for a weakened smallpox vaccine for patients that are unable to use conventional full-strength vaccines. The group will be co-developing MVA3000 with its process development and manufacturing partner Baxter Healthcare. MVA3000 is a vaccine aimed at people with disorders of the immune system or skin conditions such as eczema.
